

Francesca Maria Quaglia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9263024/publications.pdf>

Version: 2024-02-01

25
papers

753
citations

687335

13
h-index

552766

26
g-index

29
all docs

29
docs citations

29
times ranked

1478
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
2	In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. <i>Blood</i> , 2017, 129, 3495-3498.	1.4	74
3	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
4	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.	7.2	56
5	Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease. <i>Stem Cells</i> , 2020, 38, 698-711.	3.2	48
6	Efficacy of Râ€BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. <i>British Journal of Haematology</i> , 2020, 189, 684-688.	2.5	43
7	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. <i>Journal of Hematology and Oncology</i> , 2016, 9, 88.	17.0	35
8	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	2.5	34
9	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	1.4	33
10	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. <i>Cancers</i> , 2020, 12, 2913.	3.7	24
11	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. <i>Leukemia and Lymphoma</i> , 2016, 57, 2685-2688.	1.3	20
12	Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1958.	3.7	20
13	Continuous treatment with Ibrutinib in 100 untreated patients with <i>TP</i>53 disrupted chronic lymphocytic leukemia: A realâ€life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	14
14	An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. <i>Oncotarget</i> , 2017, 8, 28008-28020.	1.8	13
15	Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vasoâ€Occlusive Crisis in Sickle Cell Disease. <i>Pain Practice</i> , 2016, 16, 680-687.	1.9	12
16	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. <i>Haematologica</i> , 2022, 107, 1470-1473.	3.5	12
17	Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 34398-34412.	1.8	11
18	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103377.	4.4	10

#	ARTICLE	IF	CITATIONS
19	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. Hematological Oncology, 2021, 39, 570-574.	1.7	9
20	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology, 2021, 39, 326-335.	1.7	8
21	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. Leukemia and Lymphoma, 2021, 62, 3474-3483.	1.3	7
22	IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016047.	1.3	6
23	Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology. Scientific Reports, 2021, 11, 23823.	3.3	4
24	Mantle cell lymphoma patients in first relapse: we pretty much know what to do. Oncotarget, 2021, 12, 1724-1726.	1.8	2
25	Bendamustine plus rituximab: is it a BRIGHT idea?. Chinese Clinical Oncology, 2020, 9, 22-22.	1.2	0